First, the lack of clinical data prevented us from examining relationship between CAD/POLD2 and tumor stage features, lymph node status, as well as progression- and relapse-free survival; the small sample sizes also prevented our ability to adequately conduct simultaneous multivariate analysis for CAD and POLD2. This evidence concerns the gene POLD2 and neoplasm.